ライフサイエンスコーパス: serum marker

1 by liver biopsy, transient elastography, or serum markers).

2 s instituted prospectively on the basis of a serum marker.

3 CT perfusion parameters with tumor grade and serum markers.

4 relation between CT perfusion parameters and serum markers.

5 Parameters were correlated with HCC serum markers.

6 ondiagnostic electrocardiograms and negative serum markers.

7 ssion was documented by biopsy or increasing serum markers.

8 sociations between cardiac SSc and candidate serum markers.

9 sociations between cardiac SSc and candidate serum markers.

10 ns, however, unclear and we lack mechanistic serum markers.

11 with further improvement upon integration of serum markers.

12 lates with the body mass index and metabolic serum markers.

13 d by improvements in noninvasive imaging and serum markers.

14 r cannot explain racial disparities in these serum markers.

15 avior were comparable with that of other IBD serum markers.

16 ere documented in blood eosinophil counts or serum markers after eHF intake.

17 Malnutrition was measured using serum markers (albumin <3.5 g/dL) as well as body mass i

18 However, when the values of known serum markers alpha fetoprotein, des-gamma carboxyprothr

19 Serum markers also appear to provide useful prognostic i

20 patients with advanced fibrosis as a single serum marker and in combination with APRI and FIB-4.

21 naire and metabolic risks were determined by serum markers and anthropometric measures at pre- and po

22 sure mitochondrial absorbance, infarct size, serum markers and apoptotic index.

23 c inflammation was assessed by histology and serum markers and fibrosis by collagen proportionate are

24 Secondary outcomes included serum markers and histologic measures of fibrosis improv

25 At the current writing, serum markers and imaging methods are available and incr

26 A combination of serum markers and imaging tools appears useful in reduci

27 ltahepa) or control mice, based on levels of serum markers and microscopic and histologic analysis of

28 nd still enrolling HeadSMART II (Head Injury Serum Markers and Multi-modalities for Assessing Respons

29 The relationship between serum markers and quantitative hepatic collagen content

30 e of the newer noninvasive methods including serum markers and radiologic tests.

31 tion for treatment as they rely primarily on serum markers and radiologist-defined imaging features.

32 ve adverse vascular effects not reflected in serum markers and that nonlipid macronutrients can modul

33 eviews that assessed the association between serum markers and the presence of and/or predicting the

34 lgorithms combining standard ultrasound with serum markers and transient elastography (TE) for detect

35 A sequential approach or the combination of serum markers and transient elastography is able to sign

36 se, including quantitative imaging features, serum markers, and functional biomarkers, is needed to o

37 ue to frequent late-stage diagnosis, lack of serum markers, and limited information regarding biliary

38 dditional parameters including tumor biopsy, serum markers, and subclassification of current staging

39 s of recovery, such as genetic associations, serum markers, and the impact of medical therapy or vent

40 Available diagnostic serum markers are not sensitive or specific enough, and

41 Ghr(-/-);Mdr2(-/-) mice showed elevated serum markers associated with liver damage and cholestas

42 Serum markers associated with the acute proinflammatory

43 Guidelines recommend that testing for serum markers be repeated every 12-24 weeks during antiv

44 More-reliable serum markers, better tumour localisation and identifica

45 nflammatory markers, and neurological-damage serum markers between never-ventilated subjects, subject

46 We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of ea

47 These serum markers can be used as a non-invasive method in th

48 erated diagnostic protocols with new cardiac serum markers can detect myocardial ischemia or infarcti

49 ine decarboxylase (HDC) gene expression; and serum markers (CCL2, CCL5, CCL11, IL-3, and thymic strom

50 od to assess the prognostic value of CTC and serum marker changes during treatment.

51 Serum marker determinations at baseline and 60-min after

52 Frequent serum marker determinations to estimate marker decline d

53 One hour after intervention, serum markers did not differ between interventions.

54 vs non-neutrophilic asthma phenotypes, while serum markers did not differ.

55 The relationships between IL-23 blockade, serum markers downstream of IL-23 signaling, and withdra

56 nd magnetic resonance elastography (MRE) and serum markers e.g. APRI and FIB-4 scores were assessed a

57 hy scans, bronchoalveolar lavage and various serum markers (e.g., surfactant protein D and KL-6) each

58 es emphasized are computer-generated models, serum markers, echocardiography, and nuclear imaging in

59 Among nonlipid serum markers examined, only C-reactive protein levels a

60 gression including metabolomics, circulating serum markers, exercise physiology, and both structural

61 aimed to reveal a potential new inflammatory serum marker for assessing disease activity and severity

62 ific antigen (PSA) has been widely used as a serum marker for cancer of the prostate.

63 e cancer (PCa) and is the most commonly used serum marker for cancer.

64 PCT is a reliable serum marker for determining the presence or absence of

65 Chromogranin A appears to be the most useful serum marker for diagnosis, staging, and monitoring.

66 We have identified a potential serum marker for glioblastoma multiforme (GBM) using mic

67 The conventional serum marker for HB, alpha-fetoprotein (AFP), has its li

68 concluded that GPC3 is inferior to AFP as a serum marker for HB.

69 increasing grade of ACR and may be a useful serum marker for intestinal rejection.

70 There is no known serum marker for intestinal rejection.

71 d and neck cancer and represents a promising serum marker for monitoring affected patients.

72 alyl-Lewis a), which is used as a prognostic serum marker for pancreatic cancer, and its isomer sialy

73 results merit further investigation of this serum marker for potential diagnostic and prognostic pur

74 tate-specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa) but has limited s

75 tate specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa), but has limited

76 tate-specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa), but in the criti

77 , previously known as CA125, is a well-known serum marker for the diagnosis of ovarian cancer and has

78 the potential of this protein to serve as a serum marker for the early stage diagnosis of PC.

79 ApoM levels may be a useful serum marker for the identification of MODY3 patients.

80 Methods for the determination of serum markers for bone and cartilage destruction, as wel

81 veloped massive cardiac damage as defined by serum markers for cardiomyocyte cell death, electrocardi

82 y in hematopoietic tissues and are potential serum markers for certain hematopoietic malignancies.

83 This study sought to determine if serum markers for collagen I and III synthesis, the carb

84 CCSA-3 and CCSA-4 show promise as potential serum markers for detection of colorectal cancer and adv

85 the proposed intervention and identify early serum markers for each of those subgroups.The mathematic

86 ents (30%) and 3 of 59 controls (5%) without serum markers for HBV infection.

87 tly, there remains a great need for reliable serum markers for IBD.

88 nd inflammatory responses and serve as early serum markers for monitoring acute allograft rejection.

89 ntibodies against citrullinated proteins and serum markers for osteoclast-mediated bone resorption in

90 Her white blood cell count and serum markers for ovarian cancer were normal (alpha-feto

91 Detection of serum markers for pancreatic cancer has been elusive.

92 ometry successfully identified 154 potential serum markers for pancreatic cancer.

93 large-scale proteomics to identify potential serum markers for pancreatic cancer.

94 to controls, Fic(-/-) mice exhibit elevated serum markers for pancreatic dysfunction and display enh

95 ts suggest that both CYT-MAA and HMW-MAA are serum markers for residual melanoma in patients with res

96 Serum markers for the diagnosis of early HCC (<2 cm in d

97 and a literature search to select candidate serum markers for the diagnosis of lung cancer.

98 The measurement of infarct size by serum markers has multiple theoretical and practical lim

99 in whom postoperative elevations of cardiac serum markers have been correlated to medium- and long-t

100 ge of targeted therapies and as a diagnostic serum marker in cancer, is confounded by its variable tu

101 o support recommendations for using nonlipid serum markers in decisions regarding statin therapy for

102 The chosen reviews assessed serum markers in GC, and the quality assessment was cond

103 The investigated serum markers in the studies included SOD activity, sele

104 imaging data were supported by modulation of serum markers in vitro and ex vivo histopathology.

105 Serum markers include chromogranin A for neuroendocrine

106 rol and rmTSG-6-treated animals when various serum markers (including pro- and anti-inflammatory cyto

107 Novel serum markers, including C-reactive protein and homocyst

108 Analysis of serum markers indicated that 95% (84/88) had evidence of

109 neoplasia could make this protein a possible serum marker indicating the presence of high-risk premal

110 Inflammatory responses (physiological/serum markers, innate-signaling transcripts) are therefo

111 ly history of liver cancer and hepatitis B/C serum markers is associated with an over 70-fold elevate

112 Use of Feno values, bEOS counts, and serum marker levels (eg, CCL26 and CCL17) in combination

113 Furthermore, proinflammatory serum markers may be used as inclusion criteria or endpo

114 ose a paradigm to improve the sensitivity of serum marker measurement by modifying them with an exter

115 Novel serum markers need to be explored.

116 ents were analyzed for cardiac troponin I, a serum marker not detected in the blood of healthy person

117 el candidate for development as a diagnostic serum marker of early stage colon cancer.

118 FibroTest is an indirect serum marker of hepatic fibrosis.

119 nce of procalcitonin (ProCT), an established serum marker of infection, in saliva.

120 A reliable noninvasive serum marker of IRA patency is desired to permit early i

121 TT levels may be a useful serum marker of poor outcomes among Covid-19 patients.

122 e HIP1 autoantibody test may be an important serum marker of prostate cancer.

123 sTac has been used as a serum marker of T cell activation in immune disorders an

124 eptide of calcitonin, has been shown to be a serum marker of the severity and mortality of several sy

125 se Neuroimaging Initiative-1 (ADNI1) cohort, serum markers of 5-HT, tryptophan, and Kyn were measured

126 gned to assess safety, pharmacokinetics, and serum markers of angiogenesis in patients with solid tum

127 Serum markers of angiogenic activity did not provide ins

128 e consistent hyposecretors of acid, most had serum markers of atrophic gastritis.

129 n total serum bile acid (BA) concentrations, serum markers of BA synthesis and steady-state pharmacok

130 ne levels were normal (35 +/- 21 pg/ml), the serum markers of bone formation (osteocalcin and bone-sp

131 on in bone, loss of osteoblasts, and reduced serum markers of bone formation, including osteocalcin a

132 rum markers of bone resorption, but elevated serum markers of bone formation.

133 ography, and bone turnover was quantified by serum markers of bone resorption and formation via enzym

134 eoclasts, Phlpp1 deficiency did not increase serum markers of bone resorption, but elevated serum mar

135 hose discontinuing alendronate had increased serum markers of bone turnover compared with continuing

136 Serum markers of bone turnover were also determined.

137 lasts, Shn3-deficient animals show decreased serum markers of bone turnover.

138 d the dynamics of, and relationship between, serum markers of brain injury [neurofilament light (NfL)

139 In Step 1, we tested whether serum markers of cholesterol catabolism were associated

140 respective gene expression in liver and the serum markers of circadian function.

141 The goal of this study was to identify novel serum markers of colon cancers and precancerous colon ad

142 creatinine level, urinary protein level, and serum markers of disease activity.

143 -defined patient population for the study of serum markers of familial OA with respect to pathogenesi

144 hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with

145 fness by MRE and transient elastography, and serum markers of fibrosis were measured at baseline and

146 orphometry), NAFLD Activity Score (NAS), and serum markers of fibrosis.

147 re, Braak score, and 11C-PiB retention, with serum markers of glucose homeostasis using grouped and c

148 oad, and a decrease in both GCF IL-1beta and serum markers of IL-6 response.

149 cell function, lymphocyte surface phenotype, serum markers of immunologic activation, and viral burde

150 rt Form 36 health survey questionnaire), and serum markers of inflammation (erythrocyte sedimentation

151 Serum markers of inflammation (high-sensitivity C-reacti

152 y, high viral loads, and increased levels of serum markers of inflammation and hepatic/renal injury.

153 Serum markers of inflammation and macrophage activation.

154 Serum markers of inflammation and organ injuries that pe

155 Serum markers of inflammation and oxidation were also me

156 lack of coagulopathy, and reduced or absent serum markers of inflammation and/or hepatic/renal funct

157 atypical chemokine receptor allele increases serum markers of inflammation could lead to novel therap

158 Hormone therapy has divergent effects on serum markers of inflammation in women with CAD.

159 Anemia and serum markers of inflammation were present in all cases.

160 roups had similar fecal microbiota profiles, serum markers of inflammation, and levels of neurotrophi

161 s, and HCMV-specific immunoglobulin G (IgG), serum markers of inflammation, and mycobacterial antibod

162 fecal microbiota, urine metabolome profiles, serum markers of inflammation, neurotransmitters, and ne

163 erythematous left index finger and elevated serum markers of inflammation.

164 rains and was accompanied by an elevation of serum markers of insulin resistance, including increases

165 Serum markers of kidney injury, BUN, creatinine, and neu

166 tion analysis to address the contribution of serum markers of liver damage, high aspartate (AST, >49.

167 Knowledge of serum markers of liver decompensation would facilitate c

168 d is sufficient for preventing elevations in serum markers of liver dysfunction in this population un

169 Serum markers of liver function were used to evaluate LR

170 id not modulate baseline characteristics and serum markers of liver injury in CHC patients.

171 ung age, male sex, and advanced disease, and serum markers of liver injury, particularly bilirubin an

172 high-resolution CT (HRCT) abnormalities and serum markers of lung fibrosis.

173 rmined that DPD in mice and humans increases serum markers of metabolic health.

174 e displayed increased inflammation, enhanced serum markers of myocardial damage, and an increased inf

175 st groups with a similar trends observed for serum markers of myocardial injury and apoptotic index.

176 Serum markers of myocardial injury and inflammation (tro

177 aim of this study was to assess the role of serum markers of myocardial necrosis after cardiac surge

178 growth and should be considered as potential serum markers of neoplastic prostate diseases.

179 osition, apoptosis, histologic features, and serum markers of oxidative stress (OS) and cell death in

180 with stable plaques, and may correlate with serum markers of plaque instability and inflammation.

181 Serum markers of renal and cardiac function, oxidative s

182 to examine associations between SBI and two serum markers of renal function: Serum creatinine (SCr)

183 Serum markers of renal injury were significantly decreas

184 Currently, quantification of pretransplant serum markers of the HBV antigen load does not predict t

185 chemokine 10, in parallel with depression of serum markers of the myeloid cell activation, such as CC

186 ve developed a process for identification of serum markers of this disease based upon standardized fr

187 xtures of urinary phthalate metabolites with serum markers of thyroid function and autoimmunity.

188 Established serum markers of tumor spread were measured serially and

189 cardiolipin IgG is associated with increased serum markers of vascular inflammation, and IgG purified

190 weeks of gestation, did not reduce systemic (serum) markers of inflammation.

191 Additionally, the origin of serum markers often cannot be localized to a specific ce

192 umor cells along with reduction in malignant serum markers (osteopontin, Cxcl12) were noted.

193 To date, a number of methods including serum marker panels and ultrasound-based transient elast

194 Serum marker panels, initially developed for determining

195 iew is broad and includes topics such as the serum marker procalcitonin, gene expression profiling, m

196 A standard amphotropic vector expressing a serum marker protein, human alpha 1-antitrypsin, was inf

197 Serum markers provide an alternative way to monitor the

198 A disparate array of plasma/serum markers provides evidence for chronic inflammation

199 Two additional serum markers rapidly renormalized after polypectomy: gr

200 Serum markers related to bone turnover, calcium, phospho

201 Serum markers such as myoglobin and creatine kinase, MB

202 Previous genetic studies of blood group and serum markers suggested that Jewish groups had Middle Ea

203 regarding the measurement of infarct size by serum markers, technetium-99m sestamibi single-photon em

204 mes, it is desirable to identify a sensitive serum marker that is closely related to the degree of my

205 proteomic analysis in an attempt to discover serum markers that can assist in the early detection of

206 Finally, we sought to identify serum markers that differentiate SIRS with and without i

207 Longitudinal physiologic and serum markers, time of death.

208 Although PSA is the most widely used serum marker to detect and follow patients with prostati

209 We assessed the added value of CTCs or serum markers to prognostic clinicopathological models i

210 n characterized in mastocytosis, such as the serum marker tryptase and the immune checkpoint molecule

211 Assessment of liver fibrosis with multiple serum markers used in combination is sensitive, specific

212 sent, specificity and sensitivity of current serum markers used to diagnose PSC are limited and often

213 iagnosis of GC, this umbrella focuses on the serum markers valuable in GC, for whether detecting or p

214 A panel of 10 diabetes and obesity serum markers was determined using MAGPIX.

215 d the slope of increase over 60 min for each serum marker were significantly higher in patients with

216 of detection of Down's syndrome for the five serum markers were as follows: 17 percent for alpha-feto

217 CCL2 levels (but not those of other serum markers) were significantly higher during anaphyla

218 ated significantly and better than any other serum marker with apoptosis and liver damage, such as ba

219 ent of cardiac troponin I (cTnI), which is a serum marker with high sensitivity and specificity for c

220 The integration of these serum markers with clinical parameters into a new multi-

221 The stronger correlation of the serum markers with Ishak scores suggests that serum fibr

222 in saturation (SaO(2)) during sleep] and all serum markers with pain thresholds and tolerances at bas

223 ular epithelial cells, and lower cholestasis serum markers within 2 weeks after DDC treatment.

224 assess whether the immediate availability of serum markers would increase the appropriate use of thro